Description
The Alemtuzumab297.rMAb (also known as, Alemtuzumab N297A Biosimilar.rMAb) is a research grade humanized recombinant human IgG1, kappa antibody that specifically recognizes the extracellular domain of human CD52, similarly to the therapeutic Alemtuzumab antibody. The Alemtuzumab297.rMAb uses variable region sequences from Alemtuzumab and constant region consensus sequences from human IgG1 kappa. The asparagine at position 297 of the constant heavy chain has been replaced with alanine (N297A) to further reduce Fc receptor interactions. The CD52 antigen is a 25-29 kDa N-glycosylated, GPI-linked protein that is also known as Cambridge pathology antigen 1 (CAMPATH-1 antigen), or Human epididymis-specific protein 5 (He5). It is expressed on thymocytes, lymphocytes, monocytes, macrophages, dendritic cells, and eosinophils, but is weakly or not expressed on neutrophils, erythrocytes, platelets, or hematopoietic stem cells. CD52 is variably expressed on malignant lymphoid cells and serves as a target for therapeutic CD52-specific antibodies. The Alemtuzumab297.rMAb is intended for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385). Note: When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed. For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
3. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. For U.S. patents that may apply, see bd.com/patents.
